Answers are grounded in this paper and cite their sources.
Background Late-onset first-episode mania (LOFEM) in adults aged ≥50 years is rare and frequently complicated by cerebrovascular lesions, multimorbidity, and polypharmacy, all of which increase the risk of adverse events such as rhabdomyolysis. Differentiating agitation-related from drug-induced creatine kinase (CK) elevation in this setting is clinically challenging but critical for safe pharmacotherapy. This retrospective, post-discharge pharmacist-led multidimensional assessment explored how etiological differentiation could be achieved. Case presentation A 60-year-old woman with no prior psychiatric history presented with first-episode mania. On day 2, after a single 50 mg dose of quetiapine and an intramuscular injection of diazepam on day 1 (baseline CK was not measured), her CK was 780.9 U/L and myoglobin 112.61 ng/mL, consistent with mild biochemical rhabdomyolysis without acute kidney injury. Quetiapine was continued and titrated to 200 mg/day, combined with valproate and modified electroconvulsive therapy. CK normalized by day 21 and the patient achieved full recovery of psychiatric symptoms. Conclusions A post-discharge, retrospective multidimensional pharmaceutical assessment (Naranjo scale, Beers criteria, multi-database drug-drug interaction analysis, and geriatric dose evaluation) indicated that the overall picture was most consistent with mild biochemical rhabdomyolysis related to manic agitation and dehydration/exertion, with intramuscular diazepam as an additional confounder. Quetiapine cannot be excluded as a contributor. NMS was not clinically supported.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: